Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Featured News

    Efficient Influenza B Cell Culture Vaccine Production

    By Global Biodefense StaffDecember 6, 2016
    Influenza Virus
    Credit: Shutterstock
    Share
    Facebook LinkedIn Reddit Email
    Influenza Virus
    Credit: Shutterstock

    A team of researchers has developed technology that could improve the production of Influenza B vaccines by allowing producers to grow vaccine viruses at high yield in mammalian cell culture rather than in eggs.

    Led by Yoshihiro Kawaoka, professor of pathobiological sciences at the University of Wisconsin-Madison School of Veterinary Medicine, the approach should improve the ability of seasonal vaccines to protect against influenza A and B because vaccine viruses grown in mammalian cell culture are less likely to mutate compared to those grown in eggs. Mutations can lead to vaccine viruses that no longer match the intended strains of influenza.

    “We want to provide a system that produces influenza vaccines that are more efficacious,” says Kawaoka. “It is better to produce influenza viruses for vaccine production in cells instead of eggs, but the problem is that influenza virus does not grow well in cell culture compared with embryonated eggs.”

    The new technology may overcome that challenge. Kawaoka’s team first screened influenza B viruses for random genetic mutations that led to improved replication. Using these mutants as templates, the researchers attached the genes that code for the surface proteins that trigger the human immune response (and thus offer protection in vaccinated individuals) — HA (hemagglutinin) and NA (neuraminidase).

    They then selected the combinations of backbone mutations that supported better growth in cell culture, identifying two candidate backbones that led to higher amounts of vaccine virus.

    “It may still not be perfect, but it will at least be substantially better than current vaccines,” says Kawaoka, who notes no one else has successfully tried to produce high-yield influenza B vaccine virus before now.

    Last year, his research team created a high-yield influenza A vaccine virus candidate for cell culture production.

    Kawaoka points out that more testing is required to discern whether these results would translate to increased vaccine virus yield under industrial conditions.

    Several companies and federal agencies have already contacted him about the influenza A and influenza B backbones, Kawaoka says, and he is hopeful the systems can be adopted by vaccine manufacturers and grown in cell culture facilities already available in the United States and Japan.

    Read more at PNAS: Development of high-yield influenza B virus vaccine viruses.

    Influenza Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleStrategies for Protecting African Great Apes from Ebola
    Next Article Proceedings Available for Workshop on Enhancing BioWatch Capabilities

    Related Stories

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Healthcare Workers Express Outrage at Flawed CDC Mask Guidance

    September 18, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    Oct 17
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Dispensing and Administration of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.